RMTG Regenerative Medical Technology Group Inc.

OTC Retail-Retail Stores, NEC CIK: 0001760026
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

RMTG exhibits severe financial distress with negative stockholders' equity of -$30.1M and a critical liquidity crisis (current ratio 0.09x), indicating technical insolvency. Despite 70.4% revenue growth and healthy 57.6% gross margins, the company generates a -$6.4M net loss on $3.5M revenue with negative operating cash flow of -$744.7K. Without immediate capital restructuring or substantial funding, the company lacks runway to continue operations.

Strengths

  • + 70.4% year-over-year revenue growth demonstrates strong market demand
  • + 57.6% gross margin indicates viable product and pricing power
  • + Net loss improved 43.3% YoY showing operational trajectory enhancement

Risks

  • ! Negative stockholders' equity of -$30.1M indicates technical insolvency with liabilities exceeding assets
  • ! Critical liquidity crisis with current ratio 0.09x leaves minimal ability to meet short-term obligations
  • ! Negative operating cash flow of -$744.7K with only $1.2M cash runway insufficient for operational sustainability

Key Metrics to Watch

Financial Metrics

Revenue
3.5M
Net Income
-6.4M
EPS (Diluted)
$-0.51
Free Cash Flow
-1.1M
Total Assets
4.5M
Cash
1.2M

Profitability Ratios

Gross Margin 57.6%
Operating Margin -15.9%
Net Margin -181.9%
ROE N/A
ROA -142.0%
FCF Margin -30.6%

Balance Sheet & Liquidity

Current Ratio
0.09x
Quick Ratio
0.08x
Debt/Equity
N/A
Debt/Assets
764.9%
Interest Coverage
-0.16x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-10T00:10:23.276094 | Data as of: 2025-09-30 | Powered by Claude AI